Custirsen Does Not Improve Overall Survival in mCRPC
The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer in a phase III trial. (Source: CancerNetwork)
Source: CancerNetwork - March 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news
Japan clears Novocure ’ s 2nd gen Optune device
Novocure (NSDQ:NVCR) said today it won approval from the Japanese Ministry of Health, Labour and Welfare for its 2nd-gen Optune device.
The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death, the St. Helier, N.J.-based company said.
The next-generation device is smaller, lighter and features a tumor treating field generator that is less than half the weight and size of the 1st-generation Optune system, NovoCure said.
“The MHLW’s approval of secon...
Source: Mass Device - March 21, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Oncology Regulatory/Compliance NovoCure Source Type: news
Fatal Neutropenic Enterocolitis With Docetaxel in France Fatal Neutropenic Enterocolitis With Docetaxel in France
Five fatal cases of neutropenic enterocolitis associated with a generic version of docetaxel have led one cancer centre to swap the drug for paclitaxel.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 20, 2017 Category: Cancer & Oncology Tags: Internal Medicine News Source Type: news
Novocure enrolls 1st patient in TTFields, chemo treatment lung cancer phase III trial
Novocure (NSDQ:NVCR) said today it enrolled the 1st patient in the phase 3 pivotal Lunar trial of its Tumor Treating Field technology for treating patients with advanced non-small cell lung cancer who have failed platinum-based therapy.
The prospective, randomized 512-patient trial from the St. Helier, N.J.-based company aims to test the safety and efficacy of its TTFields technology in combination with standard of care treatments of immune checkpoint inhibitors or docetaxel.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure enrolls 1st patient in TTFields, chemo treatment lung cancer...
Source: Mass Device - February 15, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology NovoCure Source Type: news
Docefrez (docetaxel) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 25, 2017 Category: Drugs & Pharmacology Source Type: news
Docetaxel, zoledronic acid not cost effective for prostate cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2016 Category: Drugs & Pharmacology Source Type: news
Mesothelioma Trial for Nintedanib Shows Positive Results
Researchers have reported more promising results from an international, multicenter phase II clinical trial of the drug nintedanib, moving it another step closer to standard-of-care treatment for pleural mesothelioma.
Nintedanib is a small-molecule enzyme inhibitor being studied as a way to increase the effectiveness of chemotherapy on mesothelioma and certain types of lung cancer.
Researchers presented the results earlier this month at the World Conference on Lung Cancer in Vienna, Austria.
The randomized clinical trial treated mesothelioma patients with a placebo and chemotherapy (pemetrexed/cisplatin) or nintedanib and ...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma extending mesothelioma survival mesothelioma treatment nintedanib Source Type: news
Increased TIL Levels Associated With Better Outcomes in HER2-Positive Breast Cancer
A higher quantity of stromal tumor-infiltrating lymphocytes (TILs) was associated with better overall survival in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo, along with trastuzumab and docetaxel. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news
Atezolizumab Extends Overall Survival in Advanced NSCLC
(MedPage Today) -- Median 4 months longer than with docetaxel (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 13, 2016 Category: Primary Care Source Type: news
Atezolizumab Improved Overall Survival Across Subgroups With NSCLC
The PD-L1 inhibitor atezolizumab significantly improved overall survival compared with docetaxel across subgroups of patients with non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news
Pembrolizumab in lung cancer: Indication of considerable added benefit
(Institute for Quality and Efficiency in Health Care) Advantages, e.g. in mortality, notably outweigh the disadvantages in some side effects in comparison with docetaxel. An added benefit over best supportive care is not proven. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 22, 2016 Category: Global & Universal Source Type: news
Chemical compound holds promise as cancer treatment with fewer side effects than traditional chemotherapy
A synthetic version of a rare toxin produced by a sea creature appears to hold promise for treating many different types of cancer while minimizing the harmful side effects of widely used chemotherapy drugs.A study published today in the journal Science Translational Medicine describes research on a substance called diazonamide, which prevents cell division, and was isolated from a marine animal calledDiazona angulata.Led by Patrick Harran, UCLA ’s Donald J. and Jane M. Cram Professor of Organic Chemistry, researchers produced a synthetic form of diazonamide that, in rodents, appears to be effective in fighting breast ...
Source: UCLA Newsroom: Health Sciences - November 16, 2016 Category: Universities & Medical Training Source Type: news
Docetaxel-Based Chemo Promising in Stomach and Esophageal Cancer Docetaxel-Based Chemo Promising in Stomach and Esophageal Cancer
Perioperative treatment with docetaxel-based triplet chemotherapy may beat anthracycline-based triplet chemotherapy in resectable gastric or gastro-esophageal junction adenocarcinoma, according to a randomized clinical trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 3, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news
New Lung Cancer Study May Improve Mesothelioma Therapy
New insight into the gene responsible for the most aggressive subtype of non-small cell lung cancer (NSCLC) could bring hope for mesothelioma patients.
Researchers from UT Southwestern Medical Center identified a new way to target lung cancer through the Kirsten rat sarcoma viral oncogene homolog, also known as the KRAS gene.
Tumors that carry a mutation in this gene account for about 30 percent of lung cancer cases, which are usually aggressive with a poor prognosis.
Prior to the study, scientists had difficulty targeting the gene.
The KRAS gene produces proteins called K-Ras, which influence cell division. Mutations i...
Source: Asbestos and Mesothelioma News - September 28, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: asbestos exposure asbestos lung cancer KRAS lung cancer KRAS mutation lung cancer study mesothelioma clinical trial mesothelioma research mesothelioma treatment Source Type: news
Nivolumab in advanced lung cancer: Indication of major added benefit
Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug Nivolumab than with docetaxel. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 18, 2016 Category: Science Source Type: news
